Stock A144510 GC CELL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News GC Cell Corporation

Equities

A144510

KR7144510005

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-09 pm EDT 		5-day change 1st Jan Change
33,000 KRW -3.51% Intraday chart for GC Cell Corporation -5.04% -27.47%
Feb. 26 GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj CI
Jan. 08 GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor
AQ
GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj
CI
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform
CI
GC Cell Affiliate BioCentriq Secures $29 Million in Funding Round
MT
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment
MT
GC Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
GC Cell Obtains Anti-Bribery Management System Certification from Korea Compliance Initiative
CI
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India
CI
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders.
CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion.
CI
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors
CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding
CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $80.552315 million in funding from 5AM Venture Management, LLC, venBio LLC, RA Capital Management, L.P., Medivate Partners LLC, Green Cross Holdings Corporation, Green Cross Lab Cell Corporation
CI
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell to Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
CI
Green Cross LabCell and Feldan Therapeutics Announce a Joint Research Collaboration to Develop Low Immunogenicity, High-Performance Natural Killer Anticancer Treatment
CI
Green Cross Lab Cell Corporation Announces Executive Changes
CI
Green Cross Lab Cell Corporation(KOSDAQ:A144510) added to S&P Global BMI Index
CI
GreenCross LabCell Corporation has completed an IPO in the amount of KRW 37.00 billion.
CI
Oxford BioMedica plc Enters into Research & Development Collaboration with Green Cross LabCell
CI
GreenCross LabCell Corporation has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A144510 Stock
  4. News GC Cell Corporation